-

scPharmaceuticals Inc. to Present at Upcoming Investor Conferences

BURLINGTON, Mass.--(BUSINESS WIRE)--scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, chief executive officer, will present at the following investor conferences in June:

Jefferies Virtual Healthcare Conference
Presentation: Thursday, June 4, 2020 at 10:30 AM EDT

BMO’s Virtual 2020 Prescriptions for Success Healthcare Conference
Presentation: Tuesday, June 23, 2020 at 11:30 AM EDT

A live webcast of the presentations can be accessed under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com, and will be archived for ninety days.

About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

Contacts

Katherine Taudvin, scPharmaceuticals Inc.
781-301-6706
ktaudvin@scpharma.com

Christopher F. Brinzey, Westwicke an ICR Company
339-970-2843
chris.brinzey@westwicke.com

scPharmaceuticals Inc.

NASDAQ:SCPH

Release Versions
$Cashtags

Contacts

Katherine Taudvin, scPharmaceuticals Inc.
781-301-6706
ktaudvin@scpharma.com

Christopher F. Brinzey, Westwicke an ICR Company
339-970-2843
chris.brinzey@westwicke.com

More News From scPharmaceuticals Inc.

scPharmaceuticals Announces Pricing of Public Offering of Common Stock

BURLINGTON, Mass.--(BUSINESS WIRE)--scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the pricing of an underwritten public offering of 5,780,347 shares of its common stock at a public offering price of $8.65 per share, before deducting underwriting discounts and commissions and other offering e...

scPharmaceuticals Inc. Announces Proposed Underwritten Public Offering of Common Stock

BURLINGTON, Mass.--(BUSINESS WIRE)--scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it has commenced an underwritten public offering of shares of its common stock. All shares of common stock to be sold in the offering will be offered by scPharmaceuticals. In addition, the underwriters wil...

scPharmaceuticals Inc. Reports First Quarter 2020 Financial Results and Provides Business Update

BURLINGTON, Mass.--(BUSINESS WIRE)--scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the first quarter ended March 31, 2020 and provided a business update. Business Update Remain on track to resubmit the FUROSCIX New Drug Application (NDA) under the current 505(b)(2) appro...
Back to Newsroom